Pay in 4 interest-free payments of $5.64 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Acta 1833, 150161
Pfizer needed this win badly
Here is how GLP-1 options compare, according to clinical trials: Daily oral semaglutide (Wegovy): Average weight loss of 13.6 percent of body weight after about 15 months of treatment, compared with 2.2 percent in a placebo group Average weight loss of 11.2 percent of body weight after 72 weeks of treatment, compared with 2.1 percent in the placebo group
STEP-1 followed 1,961 adults on weekly semaglutide for 68 weeks, and SURMOUNT-1 followed 2,539 adults on tirzepatide for 72 weeks
US$ 20.80
US$ 20.98
US$ 25.26
US$ 22.36
US$ 24.17
